Neurocrine Biosciences Inc (NBIX)
136.62
-2.95
(-2.11%)
USD |
NASDAQ |
May 10, 16:00
136.62
0.00 (0.00%)
After-Hours: 20:00
Neurocrine Biosciences Cash from Operations (Quarterly): 130.30M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 130.30M |
| December 31, 2023 | 123.50M |
| September 30, 2023 | 212.00M |
| June 30, 2023 | 179.60M |
| March 31, 2023 | -125.20M |
| December 31, 2022 | 143.00M |
| September 30, 2022 | 98.80M |
| June 30, 2022 | 138.10M |
| March 31, 2022 | -40.50M |
| December 31, 2021 | 4.20M |
| September 30, 2021 | 61.80M |
| June 30, 2021 | 103.20M |
| March 31, 2021 | 87.30M |
| December 31, 2020 | 94.50M |
| September 30, 2020 | -20.40M |
| June 30, 2020 | 118.90M |
| March 31, 2020 | 35.50M |
| December 31, 2019 | 97.50M |
| September 30, 2019 | 97.80M |
| June 30, 2019 | 64.20M |
| March 31, 2019 | -112.50M |
| December 31, 2018 | 50.49M |
| September 30, 2018 | 68.92M |
| June 30, 2018 | 20.48M |
| March 31, 2018 | -38.49M |
| Date | Value |
|---|---|
| December 31, 2017 | 40.58M |
| September 30, 2017 | -9.31M |
| June 30, 2017 | -48.24M |
| March 31, 2017 | -77.36M |
| December 31, 2016 | -31.62M |
| September 30, 2016 | -31.01M |
| June 30, 2016 | -14.34M |
| March 31, 2016 | -29.21M |
| December 31, 2015 | -15.20M |
| September 30, 2015 | -18.57M |
| June 30, 2015 | 13.96M |
| March 31, 2015 | -18.18M |
| December 31, 2014 | -15.31M |
| September 30, 2014 | -12.10M |
| June 30, 2014 | -9.965M |
| March 31, 2014 | -9.767M |
| December 31, 2013 | -10.88M |
| September 30, 2013 | -10.78M |
| June 30, 2013 | -9.86M |
| March 31, 2013 | 1.912M |
| December 31, 2012 | -8.909M |
| September 30, 2012 | -8.303M |
| June 30, 2012 | -6.878M |
| March 31, 2012 | -11.20M |
| December 31, 2011 | 11.02M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-125.20M
Minimum
Mar 2023
212.00M
Maximum
Sep 2023
80.20M
Average
97.65M
Median
Cash from Operations (Quarterly) Benchmarks
| Globus Medical Inc | 52.39M |
| Inspire Medical Systems Inc | 8.86M |
| AIM ImmunoTech Inc | -9.758M |
| Protalix BioTherapeutics Inc | 3.595M |
| Armata Pharmaceuticals Inc | -8.106M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -55.00M |
| Cash from Financing (Quarterly) | 69.90M |
| Free Cash Flow | 614.40M |
| Free Cash Flow Per Share (Quarterly) | 1.150 |
| Free Cash Flow to Equity (Quarterly) | 30.20M |
| Free Cash Flow to Firm (Quarterly) | 120.48M |
| Free Cash Flow Yield | 4.42% |